Related references
Note: Only part of the references are listed.Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
Naoki Horikawa et al.
BRITISH JOURNAL OF CANCER (2020)
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Angeles Alvarez Secord et al.
CLINICAL CANCER RESEARCH (2020)
Latest clinical evidence of maintenance therapy in ovarian cancer
Christine S. Walsh
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2020)
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora et al.
CLINICAL CANCER RESEARCH (2020)
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2020)
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
Jung-min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bad neighbours: hypoxia and genomic instability in prostate cancer
Jack Ashton et al.
BRITISH JOURNAL OF RADIOLOGY (2020)
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
K. N. Moore et al.
ANNALS OF ONCOLOGY (2020)
Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew et al.
ANNALS OF ONCOLOGY (2020)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2019)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
Angeles Alvarez Secord et al.
GYNECOLOGIC ONCOLOGY (2019)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker et al.
LANCET ONCOLOGY (2019)
Ovarian Cancer: An Integrated Review
Christine Stewart et al.
SEMINARS IN ONCOLOGY NURSING (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
Alexandra S. Zimmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Stergios Boussios et al.
DIAGNOSTICS (2019)
Olaparib in the treatment of ovarian cancer
Christina R. Washington et al.
FUTURE ONCOLOGY (2019)
LBA58BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
N Colombo et al.
ANNALS OF ONCOLOGY (2019)
Treatment of recurrent epithelial ovarian cancer
Sandro Pignata et al.
CANCER (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
David W. Doo et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Nintedanib for the treatment of idiopathic pulmonary fibrosis
Francesco Varone et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
PARP Inhibitors in Epithelial Ovarian Cancer
Kristin N. Taylor et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2018)
PARP Inhibitors in Ovarian Cancer
Gloria Mittica et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen et al.
CANCER JOURNAL (2018)
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17
Sandro Pignata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Renata Rodrigues da Cunha Colombo Bonadio et al.
CLINICS (2018)
IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis
Landon Browning et al.
CANCER MANAGEMENT AND RESEARCH (2018)
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth et al.
EUROPEAN JOURNAL OF CANCER (2017)
The role of Cediranib in ovarian cancer
Cecilia Orbegoso et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Niraparib for the treatment of ovarian cancer
Yada Kanjanapan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic
Angiolo Gadducci et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Anti-angiogenic agents in ovarian cancer: past, present, and future
B. J. Monk et al.
ANNALS OF ONCOLOGY (2016)
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
F. Trillsch et al.
ANNALS OF ONCOLOGY (2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann et al.
LANCET (2016)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois et al.
LANCET ONCOLOGY (2016)
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2015)
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study
James S. Ferriss et al.
GYNECOLOGIC ONCOLOGY (2015)
CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice
Yunching Chen et al.
HEPATOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Cediranib Aims for a Comeback
Charlie Schmidt
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Cediranib Aims for a Comeback
Charlie Schmidt
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Hyun-Jin Choi et al.
CANCER AND METASTASIS REVIEWS (2015)
The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression
Krzysztof Gawrychowski et al.
DISEASE MARKERS (2014)
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Richard T. Penson et al.
GYNECOLOGIC ONCOLOGY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2014)
Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Fiona Collinson et al.
CLINICAL CANCER RESEARCH (2013)
VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5
Daniel Herr et al.
GYNECOLOGIC ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy
Marius Raica et al.
PHARMACEUTICALS (2010)
The Role of Fibroblast Growth Factors in Tumor Growth
M. Korc et al.
CURRENT CANCER DRUG TARGETS (2009)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Angiopoietin-2: Development of Inhibitors for Cancer Therapy
Bo Hu et al.
CURRENT ONCOLOGY REPORTS (2009)
PARP-1 modulates deferoxamine-induced HIF-1α accumulation through the regulation of nitric oxide and oxidative stress
Ruben Martinez-Romero et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Share Paper
